|B-Cell Lymphoma Follow-Up Flow Panel
Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are CD5, CD10, CD11c, CD19, CD20, CD23, CD45, FMC-7, kappa, and lambda.
|BCL1/Cyclin D1BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections and is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator possibly by mediating the growth stimulatory effects of hormone receptor signaling. It has been found to play a major role in both breast and prostate tumorigenesis. Nuclear overexpression of BCL1 has been shown to increase the chance of prostate cancer metastasis to bone, and has been associated with poor prognosis. High nuclear expression of BCL1 is usually associated with poor prognosis.||Immunohistochemistry (IHC)|
|BTK Inhibitor Primary Susceptibility Panel
Concurrent analysis of the following by bi-directional sequencing: CARD11 exons 5 and 6, CD79B exon 5 including common Y196 mutations, CXCR4 C-terminus region, and MYD88 exon 5 including the L265P mutation.
|CD138CD138 (Syndecan-1) positively stains normal tissue including B-cell precursors and plasma cells. Positive staining in tumors includes myeloma, primary effusion lymphoma. CD138 negative staining comprises mature B-cells and lymphomas (even plasmacytoid lymphomas). Many carcinomas also express CD138.||Immunohistochemistry (IHC)|
|CD19CD19 recognizes a 95kD cell surface glycoprotein which is expressed by cells of the B-cell lineage and follicular dendritic cells. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders.||Immunohistochemistry (IHC)|
|CD20Normal cell expression of CD20 is found on most B-cells (after CD19 and CD10 expression, before CD21/22 expression and surface immunoglobulin expression) and expression is retained on mature B-cells until plasma cell development, as well as ollicular dendritic cells. In diseased cells, there is positive staining on most B-cell lymphomas, come pre-acute B lymphoblastic leukemia/ lymphoblastic lymphoma (B-ALL/LBL); lymphocyte predominant Hodgkin lymphoma, dimly expressed in T-cells (benign and neoplastic), and spindle cell thymomas. Rixtuximab treated patients may lose CD20 positivity in B cell lymphomas.||Immunohistochemistry (IHC)|
|CD22CD22 expression is restricted to normal and neoplastic B-cells and is absent from other hemopoietic cell types. In B-cell ontogeny, CD22 is first expressed in the cytoplasm of pro-B and pre-B-cells and on the surface as B-cells mature to become IgD+. It is not expressed by plasma cells. CD22 is found highly expressed in follicular, mantle and marginal zone B-cells, while germinal center B-cells are relatively weak. Its expression roughly parallels that of CD19. It is strongly expressed in hairy cell leukemia.||Immunohistochemistry (IHC)|
|CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3.||Immunohistochemistry (IHC)|
|CD5CD5, a transmembrane protein, is found on most thymocytes and immature peripheral T-cells. It stains normal B-cells of mantle zone of spleen and lymph nodes, B-cells in peritoneal and pleural cavities, and almost all T-cells. In a fetus, most B-cells in spleen and cord blood are CD5 positive. It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies, and most thymic carcinomas. CD5 is usually negative in spindle cell thymoma.||Immunohistochemistry (IHC)|
|CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells.||Immunohistochemistry (IHC)|
|CXCR4 Mutation Analysis
Bi-directional sequencing to detect nonsense, frameshift, and other mutations encoding the C-terminus of CXCR4. Analyzed range includes detection of the C1013G mutation and spans amino acids L301 to S352. Testing is available separately or in combination with three other contributory genes in the BTK Inhibitor Primary Susceptibility Panel.
|FOXP1FOX P1 (Forkheadbox-P1) is a transcription factor widely expressed in normal tissues. Its expression is commonly deregulated in malignancies. FOX P1 is differentially expressed in resting and activated B cells. FOX P1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCL) and is more common in the non-germinal center (non-GC), activated B-cell type. Loss of FOX P1 expression has been correlated with a poor prognosis in solid tumors, such as breast cancer. In contrast, high level expression of smaller isoforms of the FOX P1 protein identifies high risk patients with DLBCL. The study demonstrated a correlation between strong nuclear positivity and poor prognosis in a subset of patients with BCL2-positive, [t(14;18)]-negative, non-GC DLBCL.||Immunohistochemistry (IHC)|
|GCET1The GCET1 gene codes for a serpin expressed in germinal center (GC) B-cells. GCET1 is highly restricted to a subset of GC B-cells and GC-derived lymphomas. It is preferentially expressed in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with GC B-cell differentiation.||Immunohistochemistry (IHC)|
|IgAIgA antibody reacts with immunoglobulin Ig alpha chains. It is useful in identifying leukemias, plasmacytomas and B-cell lineage lymphomas.||Immunohistochemistry (IHC)|
|IgDIgD antibody reacts with immunoglobulin Ig delta chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas (in particular marginal zone lymphoma). Cytoplasmic staining is easily identified on paraffin tissue. IgD staining is also seen in normal mantle zone B-lymphocytes.||Immunohistochemistry (IHC)|
Probes: IgH (14q32)
|KappaAntibody to the kappa light chain of immunoglobulin is reportedly useful in the identification of leukemias, plasmacytomas and certain non-Hodgkin lymphomas. Demonstration of monotypism in lymphoid infiltrates is a surrogate for clonality, and therefore malignancy.||Immunohistochemistry (IHC)|
|KappaEach test contains a set of oligonucleotide probes. The intended target is the kappa light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations.||In Situ Hybridization (ISH)|
Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
Each test contains a set of oligonucleotide probes. The intended target is the lambda light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations.
|In Situ Hybridization (ISH)|
|LEF1LEF1 overexpression is highly associated with CLL/SLL among small B-cell lymphomas and may serve as a useful marker for diagnosis and differential diagnosis of the disease.||Immunohistochemistry (IHC)|
|Low-Grade/Small B-Cell Lymphoma FISH Panel
Probes: BCL6 (3q27) | CCND1/IgH t(11;14) IgH/BCL2 t(14;18) | MALT1 (18q21)
Probes: MALT1 (18q21)
|Non-Hodgkin's Lymphoma (NHL) FISH Panel
Probes: ALK (2p23) | BCL6 (3q27) | MYC (8q24) | CCND1/IgH t(11;14) | IgH (14q32) | IgH/BCL2 t(14;18) | MALT1 (18q21)
|PAX5Paired Box 5 (PAX5) is a B-cell specific activator protein (BSAP). In early stages of B-cell development, PAX5 influences the expression of several B-cell specific genes, such as CD19 and CD20. PAX5 is expressed primarily in pro-, pre-, and mature B-cells, but not in plasma cells. There is an excellent correlation between CD20 and PAX5 expression; however, anti-PAX5 exceeds the specificity and sensitivity of L26 (CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B-cells, including classic Hodgkin lymphoma. It is very specific to B-cell lineage and does not stain T-cells.||Immunohistochemistry (IHC)|
|Plasma Cell Add-On Flow Panel
Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD19, CD20, CD38, CD45, CD56, CD117, CD138, cKappa, and cLambda (9 markers).
|Standard Leukemia/Lymphoma Panel - 24 markers
Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.
|Universal Fusion/Expression Profile
The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.
|Wright GiemsaSpecial stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology.||Immunohistochemistry (IHC)|
Displaying 1 - 29 of 29 tests